Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Umedaptanib pegol - Ribomic

Next Previous
X
Search
Drug Profile

Umedaptanib pegol - Ribomic

Alternative Names: RBM-007

Latest Information Update: 07 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ribomic
  • Class Analgesics; Antifibrotics; Eye disorder therapies; Nucleotide aptamers
  • Mechanism of Action Fibroblast growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Achondroplasia; Wet age-related macular degeneration
  • Discontinued Fibrosis; Pain

Most Recent Events

  • 05 Dec 2023 Pooled efficacy and adverse events data from the phase I SUSHI and phase II TOFU/RAMEN/TEMPURA trials in Wet age-related macular degeneration released by Ribomic
  • 23 Jun 2023 Discontinued - Preclinical for Pain in Japan (unspecified) (Ribomic pipeline, June 2023)
  • 27 Apr 2023 Phase-II clinical trials in Achondroplasia (In children, In adolescents) in Japan (SC) (Ribomic pipeline, June 2023) (jRCT2031220291)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top